With 1.7 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.08 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $4.0253 whereas the lowest price it dropped to was $3.45. The 52-week range on INM shows that it touched its highest point at $15.70 and its lowest point at $1.72 during that stretch. It currently has a 1-year price target of $400.00. Beta for the stock currently stands at 0.36.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of INM was up-trending over the past week, with a rise of 60.59%, but this was up by 37.32% over a month. Three-month performance surged to 37.82% while six-month performance fell -8.45%. The stock lost -20.04% in the past year, while it has lost -25.39% so far this year.
Float and Shares Shorts:
At present, 1.21 million INM shares are outstanding with a float of 1.20 million shares on hand for trading. On 2025-05-30, short shares totaled 49608.0, which was 411.00003000000004 higher than short shares on 1745971200. In addition to Mr. Eric A. Adams B.S. Chem., M.I.B. as the firm’s President, CEO & Director, Ms. N. Netta Jagpal serves as its CFO & Corporate Secretary.
Institutional Ownership:
Through their ownership of 0.10182 of INM’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, INM reported revenue of $1261578.0 and operating income of -$2115330.0. The EBITDA in the recently reported quarter was -$1969182.0 and diluted EPS was -$1.94.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for INM since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$439.55628 being high and -$439.55628 being low. For INM, this leads to a yearly average estimate of -$439.55628.
